期刊文献+

活血化瘀法对急性心肌梗死病人血浆溶血磷脂酸的影响 被引量:4

Activating Blood Circulation to Dissipate blood Stasis of TCM Influence Patient with AMI on LPA in Blood
下载PDF
导出
摘要 目的通过活血化瘀结合西药治疗冠心病心肌梗死,观察溶血磷脂酸(LPA)与冠心病心肌梗死的关系,确定活血化瘀法对冠心病心肌梗死血管损伤的治疗作用。方法70例病人随机分为对照组和血塞通胶囊治疗组,对照组采用纯西药,治疗组除西药外加用相应中成药活血化瘀,观察溶血磷脂酸治疗前后水平的变化。结果对照组溶血磷脂酸水平治疗后较治疗组高(0.01<P<0.05),但比治疗前低(P<0.01),治疗组治疗后亦较治疗前低(P<0.01)。结论加用活血化瘀中成药比单纯运用西药常规疗法降低血浆溶血磷脂酸水平效果明显,两种治疗方法均可通过降低溶血磷脂酸水平,减少血管损伤,保护心肌细胞。 Objective :Through treatment AMI with Activating blood circulation to dissipate blood stasis traditional chinese drug and western medicine,We look into connection of LPA and AMI,appraise effect that Activating blood circulation to dissipate blood stasis impact patient with AMI. Method: 70 cases were classified into two groups at random,comparison group and therapy group. The former was only treated by western medicine,the latter was treated by both traditional chinese drug and western medicine,we judge the change of LPA level. Results: The LPA level of comparison group is higher than therapy group,(0.01P0.05);but it is lower than preceding therapy,(P0.01),the therapy group is lower than preceding therapy too,(P0.01).Conclusion: Activating blood circulation to dissipate blood stasis can manifest decline the level of LPA,decline injury of blood vessel,protect cardiac muscle cell.
出处 《光明中医》 2010年第2期180-181,共2页 GUANGMING JOURNAL OF CHINESE MEDICINE
基金 国家自然科学基金(30672765/C190402) 北京市自然科学基金(No7062058)
关键词 活血化瘀 心肌梗死 前胶原蛋白Ⅲ 中医药疗法 Activating blood circulation to dissipate blood stasis LPA AMI
  • 相关文献

参考文献2

二级参考文献33

  • 1何兰杰,韩变梅,马睿,李虹伟,沈潞华,陈曦.溶血磷脂酸及其受体在大鼠心肌重塑中的作用[J].基础医学与临床,2005,25(7):615-619. 被引量:5
  • 2Pages C,Simon M,Valet P,Saulnier-Blache JS.Lysophosphatidic acid synthesis and release(1).Prostaglandins Other Lipid Mediat 2001; 64:1-10.
  • 3Tigyi G.Physiological responses to lysophosphatidic acid and related glycero-phospholipids.Prostaglandins Other Lipid Mediat 2001; 64:47-62.
  • 4Seewald S,Sachinidis A,Dusing R,Ko Y,Seul C,Epping P,Vetter H.Lysophosphatidic acid and intracellular signalling in vascular smooth muscle cells.Atherosclerosis 1997; 130:121-131.
  • 5Rother E,Brandl R,Baker DL,Goyal P,Gebhard H,Tigyi G,Siess W.Subtype-selective antagonists of lysophosphatidic acid receptors inhibit platelet activation triggered by the lipid core of atherosclerotic plaques.Circulation 2003; 108:741-747.
  • 6Tigyi G,Parrill AL.Molecular mechanisms of lysophosphatidic acid action.Prog Lipid Res 2003; 42:498-526.
  • 7Karliner JS.Lysophospholipids and the cardiovascular system.Biochim Biophys Acta 2002; 1582:216-221.
  • 8Chen J,Chen Y,Han Y,Xu R,Deng L,Cong X,Yang Y,Hu S,Chen X.Specific LPA receptor subtype mediation of LPA-induced hypertrophy of cardiac myocytes and involvement of Akt and NF-κB signal pathways.J Cell Biochem(in press).
  • 9Chen J,Han Y,Zhu W,Ma R,Han B,Cong X,Hu S,Chen X.Specific receptor subtype mediation of LPA-induced dual effects in cardiac fibroblasts.FEBS Lett 2006; 580:4737-4745.
  • 10Noguchi K,Ishii S,Shimizu T.Identification of p2y9/GPR23as a novel G protein-coupled receptor for lysophosphatidic acid,structurally distant from the Edg family.J Biol Chem 2003; 278:25600-25606.

共引文献11

同被引文献59

引证文献4

二级引证文献18

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部